Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Catalyst Pharmaceutical (CPRX) reported a revenue of $141.82 million for the quarter ended December 2024, reflecting a year-over-year increase of 28.3% and surpassing the Zacks Consensus Estimate by 6.87% [1] - The earnings per share (EPS) for the quarter was $0.70, which is an increase from $0.53 in the same quarter last year, resulting in an EPS surprise of 34.62% compared to the consensus estimate of $0.52 [1] Revenue Breakdown - Product revenue from FIRDAPSE was $82.52 million, exceeding the average estimate of $81.54 million from five analysts [4] - Product revenue from FYCOMPA reached $38.22 million, surpassing the average estimate of $32.83 million [4] - Product revenue from AGAMREE was reported at $21.08 million, exceeding the estimated $17.84 million [4] - Total product revenue was $141.81 million, which is a 30% increase compared to the year-ago quarter and also above the average estimate of $132.21 million [4] - Revenue from licenses and other sources was only $0.01 million, significantly below the average estimate of $0.85 million, marking a drastic year-over-year decline of 99.3% [4] Stock Performance - Over the past month, shares of Catalyst have returned -8.9%, underperforming the Zacks S&P 500 composite, which saw a -2.3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]